Spatial dynamics of TRAIL death receptors in cancer cells.

[1]  I. Jeremias,et al.  Leukemia-initiating cells of patient-derived acute lymphoblastic leukemia xenografts are sensitive toward TRAIL. , 2012, Blood.

[2]  G. Gores,et al.  GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis , 2010, Oncogene.

[3]  R. Häsler,et al.  Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells. , 2014, Gastroenterology.

[4]  Yunfeng Zhou,et al.  Redistribution of DR4 and DR5 in lipid rafts accounts for the sensitivity to TRAIL in NSCLC cells. , 2011, International journal of oncology.

[5]  B. Moore,et al.  Antileukemic Activity and Mechanism of Drug Resistance to the Marine Salinispora tropica Proteasome Inhibitor Salinosporamide A (Marizomib) , 2014, Molecular Pharmacology.

[6]  A. Kraft,et al.  Oncogenic Ras Sensitizes Normal Human Cells to Tumor Necrosis Factor-α-Related Apoptosis-Inducing Ligand-Induced Apoptosis , 2004, Cancer Research.

[7]  J. Blenis,et al.  Death Receptor Recruitment of Endogenous Caspase-10 and Apoptosis Initiation in the Absence of Caspase-8* , 2001, The Journal of Biological Chemistry.

[8]  J. Tschopp,et al.  Oncogenic Ras inhibits Fas ligand‐mediated apoptosis by downregulating the expression of Fas , 1999, The EMBO journal.

[9]  F. Khuri,et al.  Oncogenic Ras and B-Raf Proteins Positively Regulate Death Receptor 5 Expression through Co-activation of ERK and JNK Signaling* , 2011, The Journal of Biological Chemistry.

[10]  J. Gutkind,et al.  Novel insights into G protein and G protein-coupled receptor signaling in cancer. , 2014, Current opinion in cell biology.

[11]  R. Murali,et al.  Mutations in K-Ras linked to levels of osteoprotegerin and sensitivity to TRAIL-induced cell death in pancreatic ductal adenocarcinoma cells. , 2013, Experimental and molecular pathology.

[12]  Tatsushi Yoshida,et al.  Repeated Treatment with Subtoxic Doses of TRAIL Induces Resistance to Apoptosis through Its Death Receptors in MDA-MB-231 Breast Cancer Cells , 2009, Molecular Cancer Research.

[13]  X. Gou,et al.  Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2- and RIPK1/RIP1-mediated MAPK8/JNK activation , 2012, Autophagy.

[14]  Yung-Hyun Choi,et al.  Capsaicin sensitizes TRAIL-induced apoptosis through Sp1-mediated DR5 up-regulation: involvement of Ca(2+) influx. , 2012, Toxicology and applied pharmacology.

[15]  S. Batra,et al.  The role of K-Ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines , 2011, Cancer Chemotherapy and Pharmacology.

[16]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[17]  G. Gores,et al.  Tumor Necrosis Factor-related Apoptosis-inducing Ligand Activates a Lysosomal Pathway of Apoptosis That Is Regulated by Bcl-2 Proteins* , 2007, Journal of Biological Chemistry.

[18]  L. Andĕra,et al.  Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo , 2007, British Journal of Cancer.

[19]  G. Gores,et al.  Death receptor 5 internalization is required for lysosomal permeabilization by TRAIL in malignant liver cell lines. , 2009, Gastroenterology.

[20]  S. Shirasawa,et al.  Transformation by Oncogenic RAS Sensitizes Human Colon Cells to TRAIL-induced Apoptosis by Up-regulating Death Receptor 4 and Death Receptor 5 through a MEK-dependent Pathway* , 2005, Journal of Biological Chemistry.

[21]  S. Shankar,et al.  Resveratrol Enhances Antitumor Activity of TRAIL in Prostate Cancer Xenografts through Activation of FOXO Transcription Factor , 2010, PloS one.

[22]  Y. Sun,et al.  Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells , 2011, Cell Death and Differentiation.

[23]  G. Cohen,et al.  Receptor-mediated Endocytosis Is Not Required for Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis* , 2007, Journal of Biological Chemistry.

[24]  Tatsushi Yoshida,et al.  TRAIL induces endocytosis of its death receptors in MDA-MB-231 breast cancer cells , 2009, Cancer biology & therapy.

[25]  H. Coller,et al.  Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. , 2011, Genes & development.

[26]  C. Gélinas,et al.  Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB , 2001, Nature Cell Biology.

[27]  A. López-Rivas,et al.  TAK1 activates AMPK‐dependent cytoprotective autophagy in TRAIL‐treated epithelial cells , 2009, The EMBO journal.

[28]  S. Shankar,et al.  Resveratrol Induces Growth Arrest and Apoptosis through Activation of FOXO Transcription Factors in Prostate Cancer Cells , 2010, PloS one.

[29]  S. Y. Kim,et al.  c-Cbl shRNA-expressing adenovirus sensitizes TRAIL-induced apoptosis in prostate cancer DU-145 through increases of DR4/5 , 2013, Cancer Gene Therapy.

[30]  J. Soria,et al.  Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Spandidos,et al.  Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1 , 2007, Molecular Cancer Therapeutics.

[32]  Huachuan Zheng,et al.  Cetuximab enhances TRAIL-induced gastric cancer cell apoptosis by promoting DISC formation in lipid rafts. , 2013, Biochemical and biophysical research communications.

[33]  E. Vries,et al.  Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. , 2004 .

[34]  Thomas Knight,et al.  Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting , 2014, Front. Oncol..

[35]  S. Fulda,et al.  Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer , 2001, Oncogene.

[36]  David J. Forsthoefel,et al.  A genome-wide RNAi screen reveals a Trio-regulated Rho GTPase circuitry transducing mitogenic signals initiated by G protein-coupled receptors. , 2013, Molecular cell.

[37]  H. Kalthoff,et al.  Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis , 2000, Oncogene.

[38]  I. Park,et al.  Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition. , 2014, Biochemical and biophysical research communications.

[39]  D. Stolz,et al.  Involvement of Protective Autophagy in TRAIL Resistance of Apoptosis-defective Tumor Cells* , 2008, Journal of Biological Chemistry.

[40]  Yung-Hsuan Wu,et al.  Removal of Syndecan-1 Promotes TRAIL-Induced Apoptosis in Myeloma Cells , 2012, The Journal of Immunology.

[41]  N. Naslavsky,et al.  Characterization of a nonclathrin endocytic pathway: membrane cargo and lipid requirements. , 2004, Molecular biology of the cell.

[42]  H. Gabius,et al.  Galectin-3 Precipitates as a Pentamer with Synthetic Multivalent Carbohydrates and Forms Heterogeneous Cross-linked Complexes* , 2004, Journal of Biological Chemistry.

[43]  R. K Srivastava,et al.  Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. , 2003, Cancer research.

[44]  S. Pervaiz,et al.  The three Rs along the TRAIL: Resistance, re-sensitization and reactive oxygen species (ROS) , 2012, Free radical research.

[45]  Y. Assaraf,et al.  Overcoming Multidrug Resistance via Photodestruction of ABCG2-Rich Extracellular Vesicles Sequestering Photosensitive Chemotherapeutics , 2012, PloS one.

[46]  Baolin Zhang,et al.  Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5 , 2013, Oncotarget.

[47]  S. Shankar,et al.  HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma , 2005, Oncogene.

[48]  S. Gibson,et al.  Death receptor-4 (DR4) expression is regulated by transcription factor NF-κB in response to etoposide treatment , 2008, Apoptosis.

[49]  J. Dennis,et al.  Regulation of Cytokine Receptors by Golgi N-Glycan Processing and Endocytosis , 2004, Science.

[50]  Ling Xu,et al.  Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells , 2012, Journal of Cancer Research and Clinical Oncology.

[51]  K. Schulze-Osthoff,et al.  Potential and caveats of TRAIL in cancer therapy. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[52]  R. Orlowski.  Novel agents for multiple myeloma to overcome resistance in phase III clinical trials. , 2013, Seminars in oncology.

[53]  R. Herbst,et al.  Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Y. Assaraf,et al.  Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[55]  S. Gibson,et al.  Transcription Factor NF-κB Differentially Regulates Death Receptor 5 Expression Involving Histone Deacetylase 1 , 2005, Molecular and Cellular Biology.

[56]  W. El-Deiry,et al.  Cell surface Death Receptor signaling in normal and cancer cells. , 2003, Seminars in cancer biology.

[57]  L. Andĕra,et al.  Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts , 2007, Molecular Cancer Therapeutics.

[58]  W. El-Deiry,et al.  Deficient Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Death Receptor Transport to the Cell Surface in Human Colon Cancer Cells Selected for Resistance to TRAIL-induced Apoptosis* , 2004, Journal of Biological Chemistry.

[59]  Y. Kloog,et al.  A unique platform for H-Ras signaling involving clathrin-independent endocytosis. , 2007, Molecular biology of the cell.

[60]  D. Spandidos,et al.  Regulation of Tumor Cell Sensitivity to TRAIL-Induced Apoptosis by the Metastatic Suppressor Raf Kinase Inhibitor Protein via Yin Yang 1 Inhibition and Death Receptor 5 Up-Regulation , 2007, The Journal of Immunology.

[61]  S. Shankar,et al.  Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. , 2003, Cancer research.

[62]  Jin-Ming Yang,et al.  Interaction of Beclin 1 with survivin regulates sensitivity of human glioma cells to TRAIL‐induced apoptosis , 2010, FEBS letters.

[63]  J. Taunton,et al.  ERK/Ribosomal S6 Kinase (RSK) Signaling Positively Regulates Death Receptor 5 Expression through Co-activation of CHOP and Elk1* , 2010, The Journal of Biological Chemistry.

[64]  Shi-Yong Sun,et al.  Evidence that the death receptor DR4 is a DNA damage‐inducible, p53‐regulated gene , 2001, Journal of cellular physiology.

[65]  F. Giles,et al.  Targeting sarcomas: novel biological agents and future perspectives. , 2009, Current drug targets.

[66]  Baolin Zhang,et al.  Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells , 2012, Oncotarget.

[67]  T. Takayama,et al.  Biomarkers for Predicting the Efficacy of Anti-Epidermal Growth Factor Receptor Antibody in the Treatment of Colorectal Cancer , 2014, Digestion.

[68]  P. Crespo,et al.  Activation of Ras and Rho GTPases and MAP Kinases by G-protein-coupled receptors. , 2010, Methods in molecular biology.

[69]  G. Cavet,et al.  Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL , 2007, Nature Medicine.

[70]  L. Andĕra,et al.  Arf and Rho GAP adapter protein ARAP1 participates in the mobilization of TRAIL-R1/DR4 to the plasma membrane , 2008, Apoptosis.

[71]  F. Khuri,et al.  Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. , 2007, Cancer research.

[72]  T. Shiraishi,et al.  Glycosylation modulates TRAIL-R1/death receptor 4 protein: different regulations of two pro-apoptotic receptors for TRAIL by tunicamycin. , 2007, Oncology reports.

[73]  H. Groen,et al.  TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives. , 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[74]  M. Resh.  Palmitoylation of Ligands, Receptors, and Intracellular Signaling Molecules , 2006, Science's STKE.

[75]  M. Vaysberg,et al.  EBV+ B Lymphoma Cell Lines from Patients with Post‐Transplant Lymphoproliferative Disease Are Resistant to TRAIL‐Induced Apoptosis , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[76]  M. Nau,et al.  Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. , 1999, Cancer research.

[77]  D. Lawrence,et al.  Death-receptor activation halts clathrin-dependent endocytosis , 2006, Proceedings of the National Academy of Sciences.

[78]  W. Quax,et al.  Two death-inducing human TRAIL receptors to target in cancer: similar or distinct regulation and function? , 2014, Biochemical pharmacology.

[79]  Y. Assaraf,et al.  Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924. , 2014, Biochemical pharmacology.

[80]  M. Holderfield,et al.  Mechanism and consequences of RAF kinase activation by small-molecule inhibitors , 2014, British Journal of Cancer.

[81]  Tatsushi Yoshida,et al.  Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL‐R2 gene1 , 2001, FEBS letters.

[82]  S. Shankar,et al.  Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[83]  W. El-Deiry,et al.  Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis , 2013, PloS one.

[84]  P. Hersey,et al.  Differential Localization and Regulation of Death and Decoy Receptors for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Human Melanoma Cells1 , 2000, The Journal of Immunology.

[85]  Y. Assaraf,et al.  Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance , 2014, Oncotarget.

[86]  T. Shiraishi,et al.  Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. , 2005, Cancer research.

[87]  M. Sporn,et al.  c-Jun NH2-Terminal Kinase-Mediated Up-regulation of Death Receptor 5 Contributes to Induction of Apoptosis by the Novel Synthetic Triterpenoid Methyl-2-Cyano-3,12-Dioxooleana-1, 9-Dien-28-Oate in Human Lung Cancer Cells , 2004, Cancer Research.

[88]  N. Wilson,et al.  Tumor necrosis factor: renaissance as a cancer therapeutic? , 2008, Current cancer drug targets.

[89]  W. El-Deiry,et al.  Caspase-8 regulation of TRAIL-mediated cell death. , 2012, Experimental oncology.

[90]  S. Zappavigna,et al.  Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance , 2013, Expert opinion on biological therapy.

[91]  W. El-Deiry,et al.  Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site , 2000, Oncogene.

[92]  I. Krantz,et al.  KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene , 1997, Nature Genetics.

[93]  Y. Assaraf,et al.  Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines , 2014, Journal of Hematology & Oncology.

[94]  Serge Batalov,et al.  Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. , 2003, Molecular cell.

[95]  S. S. Strom,et al.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions , 2001, Nature Medicine.

[96]  Jayanta Debnath,et al.  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is required for induction of autophagy during lumen formation in vitro. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[97]  A. Fornace,et al.  p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. , 1998, Cancer research.

[98]  Yuanfang Ma,et al.  Detachment of esophageal carcinoma cells from extracellular matrix causes relocalization of death receptor 5 and apoptosis. , 2009, World journal of gastroenterology.

[99]  W. Hou,et al.  Autophagic degradation of active caspase-8 , 2010, Autophagy.

[100]  J. Garcia,et al.  Intracellular Generation of Sphingosine 1-Phosphate in Human Lung Endothelial Cells , 2007, Journal of Biological Chemistry.

[101]  E. Henson,et al.  Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFκB activation in epithelial derived cell lines , 2002, Apoptosis.

[102]  Y. Assaraf,et al.  Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers , 2012, Cell Death and Disease.

[103]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[104]  R. Ho,et al.  Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. , 2001, Cancer research.

[105]  M. von Mehren,et al.  Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  D. Lawrence,et al.  Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. , 2000, Immunity.

[107]  S. Kim,et al.  c-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance. , 2010, Cellular signalling.

[108]  A. Kraft,et al.  RAS, MYC, and sensitivity to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. , 2005, Cancer research.

[109]  A. Yu,et al.  ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. , 2014, Current pharmaceutical design.

[110]  H. Yamaguchi,et al.  CHOP Is Involved in Endoplasmic Reticulum Stress-induced Apoptosis by Enhancing DR5 Expression in Human Carcinoma Cells* , 2004, Journal of Biological Chemistry.

[111]  S. Fulda.  Targeting extrinsic apoptosis in cancer: Challenges and opportunities. , 2015, Seminars in cell & developmental biology.

[112]  L. Diaz,et al.  Systemic use of tumor necrosis factor alpha as an anticancer agent , 2011, Oncotarget.

[113]  R. Lotan,et al.  Evidence that the human death receptor 4 is regulated by activator protein 1 , 2002, Oncogene.

[114]  D. Bar-Sagi,et al.  RAS oncogenes: weaving a tumorigenic web , 2011, Nature Reviews Cancer.

[115]  M. Siegelin.  Utilization of the cellular stress response to sensitize cancer cells to TRAIL-mediated apoptosis , 2012, Expert opinion on therapeutic targets.

[116]  H. Popper,et al.  Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy. , 2009, Lung cancer.

[117]  J. Downward.  Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.

[118]  K. Ramana,et al.  Aldose reductase inhibition enhances TRAIL-induced human colon cancer cell apoptosis through AKT/FOXO3a-dependent upregulation of death receptors. , 2013, Free radical biology & medicine.

[119]  Y. Kloog,et al.  Ras and autophagy in cancer development and therapy , 2014, Oncotarget.

[120]  Robert G. Parton,et al.  GTP-dependent segregation of H-ras from lipid rafts is required for biological activity , 2001, Nature Cell Biology.

[121]  William P. Bozza,et al.  H-Ras regulation of TRAIL death receptor mediated apoptosis , 2014, Oncotarget.

[122]  H. Ford,et al.  On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics , 2013, Oncogene.

[123]  G. Peters,et al.  Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer. , 2012, Biochemical pharmacology.

[124]  T. Mitsudomi,et al.  Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation , 2010, Cancer and Metastasis Reviews.

[125]  T. Daniels,et al.  Inhibition of Yin Yang 1-Dependent Repressor Activity of DR5 Transcription and Expression by the Novel Proteasome Inhibitor NPI-0052 Contributes to its TRAIL-Enhanced Apoptosis in Cancer Cells1 , 2008, The Journal of Immunology.

[126]  M. Linden,et al.  Utilization of Translational Bioinformatics to Identify Novel Biomarkers of Bortezomib Resistance in Multiple Myeloma , 2014, Journal of Cancer.

[127]  H. Ford,et al.  TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[128]  Baolin Zhang,et al.  TRAIL Resistance of Breast Cancer Cells Is Associated with Constitutive Endocytosis of Death Receptors 4 and 5 , 2008, Molecular Cancer Research.

[129]  H. Nakano,et al.  Importin β1 Protein-mediated Nuclear Localization of Death Receptor 5 (DR5) Limits DR5/Tumor Necrosis Factor (TNF)-related Apoptosis-inducing Ligand (TRAIL)-induced Cell Death of Human Tumor Cells* , 2011, The Journal of Biological Chemistry.